Background <p>Intratumoral regulatory T cells (Tregs) are associated with diminished antitumor immunity and poor prognosis in many cancers, with tumor-infiltrating effector Tregs expressing high levels of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). While Treg depletion is a promising strategy for cancer immunotherapy, systemic Treg depletion may lead to severe autoimmune toxicity. Therefore, to selectively deplete intratumoral Tregs, we used extracellular ATP…
ROSE12, a novel anti-CTLA-4 Fc{gamma}Rs binding-enhanced antibody activated by extracellular adenosine triphosphate, shows tumor-selective regulatory T-cell depletion and antitumor efficacy without systemic immune activation
Journal for ImmunoTherapy of Cancer | | Hayashi, H., Tatsumi, K., Katada, H., Matsuda, Y., Tsunenari, T., Honda, M., Nemoto, T., Shimizu, S., Miura-Okuda, M., Ikuta, Y., Ito, A., Ogami, C., Kato, C., Kamimura, M., Kibayashi, T., Kubo, C., Komatsu, S., Komori, Y., Shinozuka, J., Susumu, H., Tanno, H., Tomii, Y., Nakagawa, K., Nagano, H., Nanami, M., Nishito, Y., Fujisawa, N., Matsushita, T., Michisaka, S., Yamazaki, M., Yoshimoto, M., Wakatsuki, H., Wakabayashi, T., Wada, N. A., Ueda, O., Konishi, H., Kashima, K., Tanaka, H., Endo, M., Kitazawa, T., Sakaguchi, S., Kamata-Sakurai, M., Igawa, T.
Topics: immunotherapy, chemotherapy, research
Read the full article at Journal for ImmunoTherapy of Cancer